Misplaced Pages

Tebanicline: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 16:24, 6 June 2023 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,805 edits consistent citation formatting← Previous edit Latest revision as of 15:57, 7 November 2023 edit undoOAbot (talk | contribs)Bots441,761 editsm Open access bot: doi updated in citation with #oabot. 
Line 37: Line 37:
'''Tebanicline''' ('''ebanicline''', '''ABT-594''') is a potent synthetic nicotinic (non-opioid) analgesic drug developed by ]. It was developed as a less toxic ] of the potent ]-derived compound ], which is about 200 times stronger than ] as an ], but produces extremely dangerous toxic side effects.<ref>{{cite journal | vauthors = Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD, Williams M, Arneric SP | display-authors = 6 | title = Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors | journal = Science | volume = 279 | issue = 5347 | pages = 77–81 | date = January 1998 | pmid = 9417028 | doi = 10.1126/science.279.5347.77 | bibcode = 1998Sci...279...77B }}</ref><ref>{{cite journal | vauthors = Holladay MW, Wasicak JT, Lin NH, He Y, Ryther KB, Bannon AW, Buckley MJ, Kim DJ, Decker MW, Anderson DJ, Campbell JE, Kuntzweiler TA, Donnelly-Roberts DL, Piattoni-Kaplan M, Briggs CA, Williams M, Arneric SP | display-authors = 6 | title = Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors | journal = Journal of Medicinal Chemistry | volume = 41 | issue = 4 | pages = 407–12 | date = February 1998 | pmid = 9484491 | doi = 10.1021/jm9706224 }}</ref> Like epibatidine, tebanicline showed potent analgesic activity against ] in both animal and human trials, but with far less toxicity than its parent compound.<ref>{{cite journal | vauthors = Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, Piattoni-Kaplan M, McKenna DG, Wasicak JT, Holladay MW, Williams M, Arneric SP | display-authors = 6 | title = ABT-594 : a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 285 | issue = 2 | pages = 777–86 | date = May 1998 | pmid = 9580626 | url = http://jpet.aspetjournals.org/content/285/2/777.long }}</ref><ref>{{cite journal | vauthors = Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, Lynch JK, Wasicak JT, Lin NH, Arnold WH, Holladay MW, Williams M, Arneric SP | display-authors = 6 | title = ABT-594 : a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 285 | issue = 2 | pages = 787–94 | date = May 1998 | pmid = 9580627 | url = http://jpet.aspetjournals.org/content/285/2/787.long }}</ref><ref>{{cite journal | vauthors = Decker MW, Bannon AW, Buckley MJ, Kim DJ, Holladay MW, Ryther KB, Lin NH, Wasicak JT, Williams M, Arneric SP | display-authors = 6 | title = Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice | journal = European Journal of Pharmacology | volume = 346 | issue = 1 | pages = 23–33 | date = April 1998 | pmid = 9617748 | doi = 10.1016/S0014-2999(98)00042-9 }}</ref><ref>{{cite journal | vauthors = Kesingland AC, Gentry CT, Panesar MS, Bowes MA, Vernier JM, Cube R, Walker K, Urban L | display-authors = 6 | title = Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain | journal = Pain | volume = 86 | issue = 1–2 | pages = 113–8 | date = May 2000 | pmid = 10779668 | doi = 10.1016/s0304-3959(00)00233-5 | s2cid = 26170267 }}</ref><ref>{{cite journal| vauthors = Sorbera LA, Revel L, Leeson P, Castaner J |title=ABT-594|journal=Drugs of the Future|volume=26|issue=10|pages=927|doi=10.1358/dof.2001.026.10.640317|year=2001}}</ref><ref>{{cite journal | vauthors = Lynch JJ, Wade CL, Mikusa JP, Decker MW, Honore P | title = ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model | journal = European Journal of Pharmacology | volume = 509 | issue = 1 | pages = 43–8 | date = February 2005 | pmid = 15713428 | doi = 10.1016/j.ejphar.2004.12.034 }}</ref> It acts as a ] at neuronal ]s, binding to both the ] and the ] ].<ref>{{cite journal | vauthors = Jain KK | title = Modulators of nicotinic acetylcholine receptors as analgesics | journal = Current Opinion in Investigational Drugs | volume = 5 | issue = 1 | pages = 76–81 | date = January 2004 | pmid = 14983978 }}</ref> '''Tebanicline''' ('''ebanicline''', '''ABT-594''') is a potent synthetic nicotinic (non-opioid) analgesic drug developed by ]. It was developed as a less toxic ] of the potent ]-derived compound ], which is about 200 times stronger than ] as an ], but produces extremely dangerous toxic side effects.<ref>{{cite journal | vauthors = Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD, Williams M, Arneric SP | display-authors = 6 | title = Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors | journal = Science | volume = 279 | issue = 5347 | pages = 77–81 | date = January 1998 | pmid = 9417028 | doi = 10.1126/science.279.5347.77 | bibcode = 1998Sci...279...77B }}</ref><ref>{{cite journal | vauthors = Holladay MW, Wasicak JT, Lin NH, He Y, Ryther KB, Bannon AW, Buckley MJ, Kim DJ, Decker MW, Anderson DJ, Campbell JE, Kuntzweiler TA, Donnelly-Roberts DL, Piattoni-Kaplan M, Briggs CA, Williams M, Arneric SP | display-authors = 6 | title = Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors | journal = Journal of Medicinal Chemistry | volume = 41 | issue = 4 | pages = 407–12 | date = February 1998 | pmid = 9484491 | doi = 10.1021/jm9706224 }}</ref> Like epibatidine, tebanicline showed potent analgesic activity against ] in both animal and human trials, but with far less toxicity than its parent compound.<ref>{{cite journal | vauthors = Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, Piattoni-Kaplan M, McKenna DG, Wasicak JT, Holladay MW, Williams M, Arneric SP | display-authors = 6 | title = ABT-594 : a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 285 | issue = 2 | pages = 777–86 | date = May 1998 | pmid = 9580626 | url = http://jpet.aspetjournals.org/content/285/2/777.long }}</ref><ref>{{cite journal | vauthors = Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, Lynch JK, Wasicak JT, Lin NH, Arnold WH, Holladay MW, Williams M, Arneric SP | display-authors = 6 | title = ABT-594 : a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 285 | issue = 2 | pages = 787–94 | date = May 1998 | pmid = 9580627 | url = http://jpet.aspetjournals.org/content/285/2/787.long }}</ref><ref>{{cite journal | vauthors = Decker MW, Bannon AW, Buckley MJ, Kim DJ, Holladay MW, Ryther KB, Lin NH, Wasicak JT, Williams M, Arneric SP | display-authors = 6 | title = Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice | journal = European Journal of Pharmacology | volume = 346 | issue = 1 | pages = 23–33 | date = April 1998 | pmid = 9617748 | doi = 10.1016/S0014-2999(98)00042-9 }}</ref><ref>{{cite journal | vauthors = Kesingland AC, Gentry CT, Panesar MS, Bowes MA, Vernier JM, Cube R, Walker K, Urban L | display-authors = 6 | title = Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain | journal = Pain | volume = 86 | issue = 1–2 | pages = 113–8 | date = May 2000 | pmid = 10779668 | doi = 10.1016/s0304-3959(00)00233-5 | s2cid = 26170267 }}</ref><ref>{{cite journal| vauthors = Sorbera LA, Revel L, Leeson P, Castaner J |title=ABT-594|journal=Drugs of the Future|volume=26|issue=10|pages=927|doi=10.1358/dof.2001.026.10.640317|year=2001}}</ref><ref>{{cite journal | vauthors = Lynch JJ, Wade CL, Mikusa JP, Decker MW, Honore P | title = ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model | journal = European Journal of Pharmacology | volume = 509 | issue = 1 | pages = 43–8 | date = February 2005 | pmid = 15713428 | doi = 10.1016/j.ejphar.2004.12.034 }}</ref> It acts as a ] at neuronal ]s, binding to both the ] and the ] ].<ref>{{cite journal | vauthors = Jain KK | title = Modulators of nicotinic acetylcholine receptors as analgesics | journal = Current Opinion in Investigational Drugs | volume = 5 | issue = 1 | pages = 76–81 | date = January 2004 | pmid = 14983978 }}</ref>


Tebanicline progressed to Phase II clinical trials in humans,<ref>{{cite journal | vauthors = Decker MW, Meyer MD, Sullivan JP | title = The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control | journal = Expert Opinion on Investigational Drugs | volume = 10 | issue = 10 | pages = 1819–30 | date = October 2001 | pmid = 11772288 | doi = 10.1517/13543784.10.10.1819 | s2cid = 24924290 }}</ref> but was dropped from further development due to unacceptable incidence of ] side effects.<ref>{{cite journal| vauthors = Meyer MD |title=Neuronal nicotinic acetylcholine receptors as a target for the treatment of neuropathic pain|journal=Drug Development Research|date=1 April 2006|issn=1098-2299|pages=355–359|volume=67|issue=4|doi=10.1002/ddr.20099|s2cid=84222640}}</ref> However, further research in this area is ongoing,<ref>{{cite journal | vauthors = Baraznenok IL, Jonsson E, Claesson A | title = 3-(2,5-Dihydro-1H-pyrrol-2-ylmethoxy)pyridines: synthesis and analgesic activity | journal = Bioorganic & Medicinal Chemistry Letters | volume = 15 | issue = 6 | pages = 1637–40 | date = March 2005 | pmid = 15745813 | doi = 10.1016/j.bmcl.2005.01.058 }}</ref><ref>{{cite journal | vauthors = Zhang CX, Ge ZM, Cheng TM, Li RT | title = Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594 | journal = Bioorganic & Medicinal Chemistry Letters | volume = 16 | issue = 7 | pages = 2013–6 | date = April 2006 | pmid = 16412637 | doi = 10.1016/j.bmcl.2005.12.073 }}</ref><ref>{{cite journal | vauthors = Bunnelle WH, Daanen JF, Ryther KB, Schrimpf MR, Dart MJ, Gelain A, Meyer MD, Frost JM, Anderson DJ, Buckley M, Curzon P, Cao YJ, Puttfarcken P, Searle X, Ji J, Putman CB, Surowy C, Toma L, Barlocco D | display-authors = 6 | title = Structure-activity studies and analgesic efficacy of N-(3-pyridinyl)-bridged bicyclic diamines, exceptionally potent agonists at nicotinic acetylcholine receptors | journal = Journal of Medicinal Chemistry | volume = 50 | issue = 15 | pages = 3627–44 | date = July 2007 | pmid = 17585748 | doi = 10.1021/jm070018l }}</ref><ref>{{cite journal | vauthors = Joshi SK, Mikusa JP, Weaver B, Honore P | title = Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain | journal = The Journal of Pain | volume = 9 | issue = 2 | pages = 146–56 | date = February 2008 | pmid = 18088559 | doi = 10.1016/j.jpain.2007.09.004 }}</ref> and the development of nicotinic acetylcholine receptor agonists is ongoing.<ref>{{cite journal | vauthors = Lloyd GK, Williams M | year = 2000 | title = Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets | journal = Journal of Pharmacology and Experimental Therapeutics | volume = 292 | issue = 2| pages = 461–467 | pmid = 10640281 }}</ref><ref>{{cite journal | vauthors = Vincler M | title = Neuronal nicotinic receptors as targets for novel analgesics | journal = Expert Opinion on Investigational Drugs | volume = 14 | issue = 10 | pages = 1191–8 | date = October 2005 | pmid = 16185161 | doi = 10.1517/13543784.14.10.1191 | s2cid = 20618128 }}</ref><ref>{{cite journal | vauthors = Arneric SP, Holladay M, Williams M | title = Neuronal nicotinic receptors: a perspective on two decades of drug discovery research | journal = Biochemical Pharmacology | volume = 74 | issue = 8 | pages = 1092–101 | date = October 2007 | pmid = 17662959 | doi = 10.1016/j.bcp.2007.06.033 | series = Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research and Clinical Science }}</ref><ref>{{cite journal | vauthors = Wells GB | title = Structural answers and persistent questions about how nicotinic receptors work | journal = Frontiers in Bioscience | volume = 13 | issue = 13 | pages = 5479–510 | date = May 2008 | pmid = 18508600 | pmc = 2430769 | doi = 10.2741/3094 }}</ref> No agents from this class have successfully completed human clinical trials due to their unacceptable side effect profiles. Research in the area continues.<ref>{{cite journal | vauthors = Umana IC, Daniele CA, McGehee DS | date = Oct 2013 | title = Neuronal nicotinic receptors as analgesic targets: it's a winding road | journal = Biochem Pharmacol | volume = 86 | issue = 8| pages = 1208–14 | doi = 10.1016/j.bcp.2013.08.001 | pmid = 23948066 | pmc = 4127197 }}</ref> Tebanicline progressed to Phase II clinical trials in humans,<ref>{{cite journal | vauthors = Decker MW, Meyer MD, Sullivan JP | title = The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control | journal = Expert Opinion on Investigational Drugs | volume = 10 | issue = 10 | pages = 1819–30 | date = October 2001 | pmid = 11772288 | doi = 10.1517/13543784.10.10.1819 | s2cid = 24924290 }}</ref> but was dropped from further development due to unacceptable incidence of ] side effects.<ref>{{cite journal| vauthors = Meyer MD |title=Neuronal nicotinic acetylcholine receptors as a target for the treatment of neuropathic pain|journal=Drug Development Research|date=1 April 2006|issn=1098-2299|pages=355–359|volume=67|issue=4|doi=10.1002/ddr.20099|s2cid=84222640}}</ref> However, further research in this area is ongoing,<ref>{{cite journal | vauthors = Baraznenok IL, Jonsson E, Claesson A | title = 3-(2,5-Dihydro-1H-pyrrol-2-ylmethoxy)pyridines: synthesis and analgesic activity | journal = Bioorganic & Medicinal Chemistry Letters | volume = 15 | issue = 6 | pages = 1637–40 | date = March 2005 | pmid = 15745813 | doi = 10.1016/j.bmcl.2005.01.058 }}</ref><ref>{{cite journal | vauthors = Zhang CX, Ge ZM, Cheng TM, Li RT | title = Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594 | journal = Bioorganic & Medicinal Chemistry Letters | volume = 16 | issue = 7 | pages = 2013–6 | date = April 2006 | pmid = 16412637 | doi = 10.1016/j.bmcl.2005.12.073 }}</ref><ref>{{cite journal | vauthors = Bunnelle WH, Daanen JF, Ryther KB, Schrimpf MR, Dart MJ, Gelain A, Meyer MD, Frost JM, Anderson DJ, Buckley M, Curzon P, Cao YJ, Puttfarcken P, Searle X, Ji J, Putman CB, Surowy C, Toma L, Barlocco D | display-authors = 6 | title = Structure-activity studies and analgesic efficacy of N-(3-pyridinyl)-bridged bicyclic diamines, exceptionally potent agonists at nicotinic acetylcholine receptors | journal = Journal of Medicinal Chemistry | volume = 50 | issue = 15 | pages = 3627–44 | date = July 2007 | pmid = 17585748 | doi = 10.1021/jm070018l }}</ref><ref>{{cite journal | vauthors = Joshi SK, Mikusa JP, Weaver B, Honore P | title = Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain | journal = The Journal of Pain | volume = 9 | issue = 2 | pages = 146–56 | date = February 2008 | pmid = 18088559 | doi = 10.1016/j.jpain.2007.09.004 | doi-access = free }}</ref> and the development of nicotinic acetylcholine receptor agonists is ongoing.<ref>{{cite journal | vauthors = Lloyd GK, Williams M | year = 2000 | title = Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets | journal = Journal of Pharmacology and Experimental Therapeutics | volume = 292 | issue = 2| pages = 461–467 | pmid = 10640281 }}</ref><ref>{{cite journal | vauthors = Vincler M | title = Neuronal nicotinic receptors as targets for novel analgesics | journal = Expert Opinion on Investigational Drugs | volume = 14 | issue = 10 | pages = 1191–8 | date = October 2005 | pmid = 16185161 | doi = 10.1517/13543784.14.10.1191 | s2cid = 20618128 }}</ref><ref>{{cite journal | vauthors = Arneric SP, Holladay M, Williams M | title = Neuronal nicotinic receptors: a perspective on two decades of drug discovery research | journal = Biochemical Pharmacology | volume = 74 | issue = 8 | pages = 1092–101 | date = October 2007 | pmid = 17662959 | doi = 10.1016/j.bcp.2007.06.033 | series = Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research and Clinical Science }}</ref><ref>{{cite journal | vauthors = Wells GB | title = Structural answers and persistent questions about how nicotinic receptors work | journal = Frontiers in Bioscience | volume = 13 | issue = 13 | pages = 5479–510 | date = May 2008 | pmid = 18508600 | pmc = 2430769 | doi = 10.2741/3094 }}</ref> No agents from this class have successfully completed human clinical trials due to their unacceptable side effect profiles. Research in the area continues.<ref>{{cite journal | vauthors = Umana IC, Daniele CA, McGehee DS | date = Oct 2013 | title = Neuronal nicotinic receptors as analgesic targets: it's a winding road | journal = Biochem Pharmacol | volume = 86 | issue = 8| pages = 1208–14 | doi = 10.1016/j.bcp.2013.08.001 | pmid = 23948066 | pmc = 4127197 }}</ref>


== References == == References ==

Latest revision as of 15:57, 7 November 2023

Chemical compoundPharmaceutical compound
Tebanicline
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • 5-{methoxy}-2-chloropyridine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.207.679 Edit this at Wikidata
Chemical and physical data
FormulaC9H11ClN2O
Molar mass198.65 g·mol
3D model (JSmol)
SMILES
  • C1CN1COC2=CN=C(C=C2)Cl
InChI
  • InChI=1S/C9H11ClN2O/c10-9-2-1-8(5-12-9)13-6-7-3-4-11-7/h1-2,5,7,11H,3-4,6H2/t7-/m1/s1
  • Key:MKTAGSRKQIGEBH-SSDOTTSWSA-N
  (what is this?)  (verify)

Tebanicline (ebanicline, ABT-594) is a potent synthetic nicotinic (non-opioid) analgesic drug developed by Abbott. It was developed as a less toxic analog of the potent poison dart frog-derived compound epibatidine, which is about 200 times stronger than morphine as an analgesic, but produces extremely dangerous toxic side effects. Like epibatidine, tebanicline showed potent analgesic activity against neuropathic pain in both animal and human trials, but with far less toxicity than its parent compound. It acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes.

Tebanicline progressed to Phase II clinical trials in humans, but was dropped from further development due to unacceptable incidence of gastrointestinal side effects. However, further research in this area is ongoing, and the development of nicotinic acetylcholine receptor agonists is ongoing. No agents from this class have successfully completed human clinical trials due to their unacceptable side effect profiles. Research in the area continues.

References

  1. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, et al. (January 1998). "Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors". Science. 279 (5347): 77–81. Bibcode:1998Sci...279...77B. doi:10.1126/science.279.5347.77. PMID 9417028.
  2. Holladay MW, Wasicak JT, Lin NH, He Y, Ryther KB, Bannon AW, et al. (February 1998). "Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors". Journal of Medicinal Chemistry. 41 (4): 407–12. doi:10.1021/jm9706224. PMID 9484491.
  3. Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, et al. (May 1998). "ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization". The Journal of Pharmacology and Experimental Therapeutics. 285 (2): 777–86. PMID 9580626.
  4. Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, et al. (May 1998). "ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization". The Journal of Pharmacology and Experimental Therapeutics. 285 (2): 787–94. PMID 9580627.
  5. Decker MW, Bannon AW, Buckley MJ, Kim DJ, Holladay MW, Ryther KB, et al. (April 1998). "Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice". European Journal of Pharmacology. 346 (1): 23–33. doi:10.1016/S0014-2999(98)00042-9. PMID 9617748.
  6. Kesingland AC, Gentry CT, Panesar MS, Bowes MA, Vernier JM, Cube R, et al. (May 2000). "Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain". Pain. 86 (1–2): 113–8. doi:10.1016/s0304-3959(00)00233-5. PMID 10779668. S2CID 26170267.
  7. Sorbera LA, Revel L, Leeson P, Castaner J (2001). "ABT-594". Drugs of the Future. 26 (10): 927. doi:10.1358/dof.2001.026.10.640317.
  8. Lynch JJ, Wade CL, Mikusa JP, Decker MW, Honore P (February 2005). "ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model". European Journal of Pharmacology. 509 (1): 43–8. doi:10.1016/j.ejphar.2004.12.034. PMID 15713428.
  9. Jain KK (January 2004). "Modulators of nicotinic acetylcholine receptors as analgesics". Current Opinion in Investigational Drugs. 5 (1): 76–81. PMID 14983978.
  10. Decker MW, Meyer MD, Sullivan JP (October 2001). "The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control". Expert Opinion on Investigational Drugs. 10 (10): 1819–30. doi:10.1517/13543784.10.10.1819. PMID 11772288. S2CID 24924290.
  11. Meyer MD (1 April 2006). "Neuronal nicotinic acetylcholine receptors as a target for the treatment of neuropathic pain". Drug Development Research. 67 (4): 355–359. doi:10.1002/ddr.20099. ISSN 1098-2299. S2CID 84222640.
  12. Baraznenok IL, Jonsson E, Claesson A (March 2005). "3-(2,5-Dihydro-1H-pyrrol-2-ylmethoxy)pyridines: synthesis and analgesic activity". Bioorganic & Medicinal Chemistry Letters. 15 (6): 1637–40. doi:10.1016/j.bmcl.2005.01.058. PMID 15745813.
  13. Zhang CX, Ge ZM, Cheng TM, Li RT (April 2006). "Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594". Bioorganic & Medicinal Chemistry Letters. 16 (7): 2013–6. doi:10.1016/j.bmcl.2005.12.073. PMID 16412637.
  14. Bunnelle WH, Daanen JF, Ryther KB, Schrimpf MR, Dart MJ, Gelain A, et al. (July 2007). "Structure-activity studies and analgesic efficacy of N-(3-pyridinyl)-bridged bicyclic diamines, exceptionally potent agonists at nicotinic acetylcholine receptors". Journal of Medicinal Chemistry. 50 (15): 3627–44. doi:10.1021/jm070018l. PMID 17585748.
  15. Joshi SK, Mikusa JP, Weaver B, Honore P (February 2008). "Morphine and ABT-594 (a nicotinic acetylcholine agonist) exert centrally mediated antinociception in the rat cyclophosphamide cystitis model of visceral pain". The Journal of Pain. 9 (2): 146–56. doi:10.1016/j.jpain.2007.09.004. PMID 18088559.
  16. Lloyd GK, Williams M (2000). "Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets". Journal of Pharmacology and Experimental Therapeutics. 292 (2): 461–467. PMID 10640281.
  17. Vincler M (October 2005). "Neuronal nicotinic receptors as targets for novel analgesics". Expert Opinion on Investigational Drugs. 14 (10): 1191–8. doi:10.1517/13543784.14.10.1191. PMID 16185161. S2CID 20618128.
  18. Arneric SP, Holladay M, Williams M (October 2007). "Neuronal nicotinic receptors: a perspective on two decades of drug discovery research". Biochemical Pharmacology. Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research and Clinical Science. 74 (8): 1092–101. doi:10.1016/j.bcp.2007.06.033. PMID 17662959.
  19. Wells GB (May 2008). "Structural answers and persistent questions about how nicotinic receptors work". Frontiers in Bioscience. 13 (13): 5479–510. doi:10.2741/3094. PMC 2430769. PMID 18508600.
  20. Umana IC, Daniele CA, McGehee DS (Oct 2013). "Neuronal nicotinic receptors as analgesic targets: it's a winding road". Biochem Pharmacol. 86 (8): 1208–14. doi:10.1016/j.bcp.2013.08.001. PMC 4127197. PMID 23948066.
Stimulants
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Pyrrolidines
Racetams
Tropanes
Tryptamines
Others
ATC code: N06B
Analgesics (N02A, N02B)
Opioids
Opiates/opium
Semisynthetic
Synthetic
Paracetamol-type
NSAIDs
Propionates
Oxicams
Acetates
COX-2 inhibitors
Fenamates
Salicylates
Pyrazolones
Others
Cannabinoids
Ion channel
modulators
Calcium blockers
Sodium blockers
Potassium openers
Myorelaxants
Others
Nicotinic acetylcholine receptor modulators
nAChRsTooltip Nicotinic acetylcholine receptors
Agonists
(and PAMsTooltip positive allosteric modulators)
Antagonists
(and NAMsTooltip negative allosteric modulators)
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Muscarinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators
Categories: